About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

By: via Business Wire

Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt”), a social innovation platform accelerating promising health innovations, today announced that its CEO Amro Albanna will be joined for tomorrow’s Aditxt Weekly Update by Dr. Friedrich Kapp, Chris Mitton, and Evofem Biosciences’ CEO Saundra Pelletier to discuss progress in immune therapy, early disease detection and women’s health, respectively.

Event Details:

Title: Aditxt Weekly Update

Date: Friday, June 6, 2025

Time: 11:30 a.m. ET

Location: Virtual (Zoom)

Registration: Click here to register

Friedrich Kapp, M.D, Ph.D. is co-CEO of Adimune, Inc.(“Adimune”), which is advancing its lead therapeutic candidate ADI-100™ towards an Investigational New Drug (“IND”) submission to enable initiation of clinical trials with the antigen-specific gene therapy. ADI-100 is designed to restore immune tolerance in autoimmune diseases by targeting specific antigens, like glutamic acid decarboxylase, and establish tolerance in organ transplantation. Dr. Kapp, a 30+ year veteran of the pharmaceutical industry, was formerly president of the Therapeutics Business Unit at Schering AG.

Chris Mitton was appointed president of Pearsanta, Inc. (“Pearsanta”) in September 2024 to drive the advancement of its Mitomic® diagnostic tests for endometriosis and prostate cancer. A seasoned veteran of the healthcare industry with over 20 years of leadership experience in the medical diagnostics sector and a strong focus on personalized healthcare and molecular oncology diagnostics, Mr. Mitton concurrently serves as CEO of MDNA Life Sciences Inc., a pioneer in the development of liquid biopsy tests.

Saundra Pelletier is president, CEO and Chairman of the Board of Evofem Biosciences, Inc. (OTCPK: EVFM) (“EvoFem”). Her deep insight in women’s health is driven by intensive consumer research and more than three decades of commercial experience in the global markets with products addressing women’s health spanning every stage in their reproductive journey, from puberty to menopause. During her career, including her ten-year tenure at Evofem, she has launched pharmaceutical brands worldwide and expanded indications for female healthcare brands in multiple countries. Ms. Pelletier is a published author, TEDx and keynote speaker, executive coach and staunch advocate for innovation in women’s healthcare.

Pearsanta and Adimune are wholly-owned subsidiaries of Aditxt.

About Aditxt, Inc.

Aditxt, Inc. (“Aditxt”) is a social innovation platform accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health and precision health. Through the planned acquisition of Evofem BioSciences, Inc. (“EvoFem”)under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc. (jointly “the Parties”), as amended (the “A&R Merger Agreement”), Aditxt aims to introduce an additional program dedicated to women’s health. The companies are working toward a targeted close in the second half of 2025.

For more information, please visit www.aditxt.com.

Follow Aditxt on:

LinkedIn: https://www.linkedin.com/company/aditxt

Facebook: https://www.facebook.com/aditxtplatform/

Aditxt™, Adimune™, ADI-100™, Pearsanta™, are trademarks and Mitomic® is a registered trademarks of Aditxt, Inc.

Forward-Looking Statements

This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," “advancing”, "aim," “are working to,” "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company’s SEC filings, including Aditxt’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt does not undertake any duty to update any forward-looking statement except as required by law.

Contacts

More News

View More
Pfizer is Locking in New Growth Through a New Acquisition
Via MarketBeat
Topics Artificial Intelligence
Tickers MTSR PFE
Copper Giant Freeport Slumps but Analysts See 33% Upside
Via MarketBeat
Tickers FCX SCCO
The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Via MarketBeat
Topics Electric Vehicles
Tickers BYDDY LI TSLA
3 Reasons CoreWeave Could Be the Hottest AI Stock in Q4
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWV NVDA
Accenture: Undervalued GenAI Leader or Snake Eating its Own Tail?
Via MarketBeat
Tickers ACN IBM
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.